logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home

US Stock Market Move | Baird Medical (BDMD.US) rose more than 16% to become the largest supplier of microwave ablation medical devices in the country.

date
22:51 03/01/2025
avatar
GMT Eight
On Friday, BDMD.US rose more than 16% to $5.95.
On Friday, Baird Medical (BDMD.US) rose more than 16% to $5.95. Data shows that Baird Medical is a leading domestic microwave ablation medical company. In the field of treating thyroid nodules and breast nodules, Baird Medical is the largest supplier of microwave ablation medical devices in the country.
Related Articles
China Stock
Zhongjin: Middle East conflict causes global market volatility, A-share market mainly focuses on "defense and hedging" and "energy substitution" themes.
HK Stock
Net profit surged by 416%, Biocytogen Pharmaceuticals-B(02315) enters the commercialization phase.
"Capital cost is the dominant constraint": Wedbush warns that high interest rates and oil price storms are reshaping stock selection logic.
Zhongjin: Middle East conflict causes global market volatility, A-share market mainly focuses on "defense and hedging" and "energy substitution" themes.
China Stock
Net profit surged by 416%, Biocytogen Pharmaceuticals-B(02315) enters the commercialization phase.
HK Stock
"Capital cost is the dominant constraint": Wedbush warns that high interest rates and oil price storms are reshaping stock selection logic.
RECOMMEND
Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
icon
26/03/2026
Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
icon
26/03/2026
Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
icon
26/03/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.